Abstract: Objective To systematically evaluate the efficacy of cinacalcet combined with low-dose calcitriol in treating maintenance hemodialysis patients with secondary hyperparathyroidism. Methods We searched PubMed，Wanfang，and CNKI databases to collect clinical research results on comparing the efficacy of cinacalcet combined with lowdose calcitriol and cinacalcet in the treatment of SHPT in hemodialysis patients. The search period was from establishing the database to November 1，2020. The Rev Man 5.1 software was used for meta-analysis. Results Finally， 10 studies were included in the metaanalysis，involving 726 patients. Meta-analysis results showed that：compared with the cinacalcet group， cinacalcet combined with low-dose calcitriol group decreased iPTH［MD = -89. 41，95%CI（ -120. 36，-58. 46），P < 0. 000 01］，increased serum calcium ［MD = 0. 37， 95%CI（0. 28，0. 46）， P < 0. 000 01］， decreased serum phosphorus ［MD = -0. 24，95%CI（ -0. 33，-0. 15），P < 0. 000 01］，decreased alkaline phosphatase ［MD = -32. 35，95%CI（-41. 52，-23. 18），P < 0. 000 01］，reduced the volume of parathyroid glands［MD = -0. 31，95%CI（-0. 39，-0. 23），P < 0. 000 01］ and reduced the incidence of adverse reactions ［OR = 0. 20，95%CI（0. 09，0. 44），P < 0. 000 1］. Conclusion The clinical efficacy of cinacalcet combined with lowdose calcitriol in the treatment of SHPT is better than that in the cinacalcet group in hemodialysis patients，and the incidence of adverse reactions is lower.

Key words: calcitriol, cinacalcet, secondary hyperparathyroidism, hemodialysis, Meta analysis